Abstract
Michael L. Cardenas, Christopher R. Spencer, Stephanie Markovina, Thomas R. Mazur, Ashley A. Weiner
Abstract
Rights: UNKNOWN · cc-by-nc-nd · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Anal cancer incidence and survival: The surveillance, epidemiology, and end results experience, 1973-2000
10.1002/cncr.20364 · 2004
Tumours of the anal canal
2000
UKCCCR Anal Canal Cancer Trial Working Party. Epidermoid anal cancer: Results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin C
10.1016/s0140-6736(96)03409-5 · 1996
10.1200/jco.1997.15.5.2040
10.1200/jco.1997.15.5.2040 · 1997
The role of mitomycin C in combination with 5-fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized Intergroup study
10.1200/jco.1996.14.9.2527 · 1996
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: A randomized controlled trial
10.1001/jama.299.16.1914 · 2008
Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Disease-free and overall survival with RT+5-FU-mitomycin versus RT+5-FU-cisplatin
10.1200/jco.2011.29.15_suppl.4005 · 2011
A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5-FU in squamous cell carcinoma of the anus (ACT II)
10.1200/jco.2009.27.18_suppl.lba4009 · 2009
RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal
10.1016/j.ijrobp.2012.09.023 · 2013
Unresolved referenced work
Kept as external metadata until matched
Radiotherapy for epidermoid carcinoma of the anus: thirty years' experience
10.1016/j.ijrobp.2008.11.047 · 2009
Predictions and patterns of recurrence after definitive chemoradiation for anal cancer
10.1016/j.ijrobp.2006.12.052 · 2007
Squamous cell carcinoma of the anal canal: Patterns and predictors of failure and implications for intensity-modulated radiation treatment and planning
10.1016/j.ijrobp.2009.09.029 · 2010
Role of positron emission tomography-computed tomography in the management of anal cancer
10.1016/j.ijrobp.2011.10.048 · 2012
FDG-FDG PET/CT in the evaluation of anal carcinoma
10.1016/j.ijrobp.2006.01.009 · 2006
Positron emission tomography/computed tomography in the staging and treatment of anal cancer
10.1016/j.ijrobp.2011.06.1955 · 2012
Tumor response and survival predicted by post-therapy FDG-FDG - PET/CT in anal cancer
10.1016/j.ijrobp.2007.09.005 · 2008
An application of changepoint methods in studying the effect of age on survival in breast cancer
10.1016/s0167-9473(98)00096-6 · 1999
Unresolved referenced work
1981
[18-F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small cell lung cancer
10.1200/jco.2005.06.129 · 2005
Prognostic significance of SUV on FDG - PET/CT in patients with esophageal cancer: A systematic review and meta-analysis
10.1097/meg.0b013e328323d6fa · 2009
Clinical utility of PET/CT in lymphoma
10.2214/ajr.09.2637 · 2010
The influence of HPV-status on outcome of anal cancer treated with radio-chemotherapy
10.1016/j.ijrobp.2014.05.139 · 2014
No additional external references are available.